{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:07:11Z","timestamp":1774379231626,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prolactin-secreting adenoma (PRLoma) can present as large and invasive neoplasm, with increased markers of cellular proliferation. First-line approach is Dopamine Agonists (DAs) treatment; however, DA-resistance has been reported, especially in male patients. Estrogens induce lactotroph cell replication and PRL secretion: the use of anti-estrogen treatment in patients with PRLoma have been described in few cases. We reported our experience regarding treatment with the aromatase inhibitor anastrozole (ANA) as add-on therapy for male patients with DA resistant PRLoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We describe four male patients (26, 38, 29 and 19\u00a0years old at diagnosis), with PRLoma (median diameter 26\u00a0mm, PRL 7730\u00a0\u03bcg\/L). They were resistant to cabergoline (CAB,\u2009&gt;\u20092\u00a0mg\/week) in terms of PRL secretion and tumor size reduction. ANA 1\u00a0mg\/day was added to the maximum tolerated dose of CAB for at least 1\u00a0year. Magnetic Resonance was performed at baseline, after 6\u00a0months of CAB\u2009+\u2009ANA combination and every 12\u00a0months afterward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PRL levels decreased in all patients after CAB\u2009+\u2009ANA (mean \u2212\u00a070%, range \u2212\u00a044\/\u2212\u00a097%), achieving a normalization of PRL levels in one case. Tumor size decreased in all cases (mean \u2212\u00a047%, range \u2212\u00a024.5\/\u2212\u00a068%). No severe adverse effects have been reported, a moderate weight gain has been observed in two cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addition of an aromatase inhibitor (ANA) to the dopamine agonist therapy improved the control of prolactin levels and induced tumour regression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-021-01165-0","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:02:40Z","timestamp":1624694560000},"page":"914-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-7796","authenticated-orcid":false,"given":"Laura","family":"Lizzul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-0492","authenticated-orcid":false,"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3815","authenticated-orcid":false,"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"12","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Li\u00e8ge. Belgium J Clin Endocrinol Metab 91(12):4769\u20134775. https:\/\/doi.org\/10.1210\/jc.2006-1668","journal-title":"Belgium J Clin Endocrinol Metab"},{"issue":"2","key":"1165_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1165_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-19-0753","volume":"182","author":"D Kim","year":"2020","unstructured":"Kim D, Ku CR, Kim K, Jung H, Lee EJ (2020) Prolactin \u22641 ng\/mL predicts macroprolactinoma reduction after cabergoline therapy. Eur J Endocrinol 182(2):177\u2013183. https:\/\/doi.org\/10.1530\/EJE-19-0753","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1165_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","volume":"39","author":"E Sala","year":"2016","unstructured":"Sala E, Bellaviti Buttoni P, Malchiodi E et al (2016) Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest 39(12):1377\u20131382. https:\/\/doi.org\/10.1007\/s40618-016-0483-z","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1165_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/cen.13240","volume":"86","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Akutsu H, Takano S et al (2017) Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol (Oxf) 86(2):207\u2013213. https:\/\/doi.org\/10.1111\/cen.13240","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1165_CR6","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721\u20134727. https:\/\/doi.org\/10.1210\/jc.2007-2758","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1165_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27\u201337. https:\/\/doi.org\/10.1007\/s11102-019-00987-3","journal-title":"Pituitary"},{"issue":"10","key":"1165_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-Tumor Endocrinopathies. N Engl J Med 382(10):937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"issue":"5","key":"1165_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160(5):747\u2013752. https:\/\/doi.org\/10.1530\/EJE-09-0012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1165_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704\u20131711. https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1165_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521\u2013535. https:\/\/doi.org\/10.1007\/s00401-017-1769-8","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1165_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","volume":"61","author":"E Sosa-Eroza","year":"2018","unstructured":"Sosa-Eroza E, Espinosa E, Ram\u00edrez-Renter\u00eda C, Mendoza V, Arreola R, Mercado M (2018) Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine 61(2):343\u2013348. https:\/\/doi.org\/10.1007\/s12020-018-1638-9","journal-title":"Endocrine"},{"issue":"2","key":"1165_CR13","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-19-0359","volume":"181","author":"G Raverot","year":"2019","unstructured":"Raverot G, Vasiljevic A, Jouanneau E, Lasolle H (2019) Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. Eur J Endocrinol 181(2):C1\u2013C3. https:\/\/doi.org\/10.1530\/EJE-19-0359","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1165_CR14","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J et al (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925. https:\/\/doi.org\/10.1210\/clinem\/dgaa805","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1165_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/CAD.0000000000000768","volume":"30","author":"F Ceccato","year":"2019","unstructured":"Ceccato F, Lombardi G, Albiger N et al (2019) Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Anticancer Drugs 30(5):533\u2013536. https:\/\/doi.org\/10.1097\/CAD.0000000000000768","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1165_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1172\/JCI14264","volume":"109","author":"AP Heaney","year":"2002","unstructured":"Heaney AP, Fernando M, Melmed S (2002) Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109(2):277\u2013283. https:\/\/doi.org\/10.1172\/JCI14264","journal-title":"J Clin Invest"},{"key":"1165_CR17","doi-asserted-by":"publisher","unstructured":"Sosic Jurjevic B, Ajdzanovic V, Miljic D, et al. 2020 Pituitary Hyperplasia, Hormonal Changes and Prolactinoma Development in Males Exposed to Estrogens An Insight From Translational Studies. Int J Mol Sci Doi: https:\/\/doi.org\/10.3390\/ijms21062024","DOI":"10.3390\/ijms21062024"},{"issue":"1","key":"1165_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1210\/endo-124-1-346","volume":"124","author":"M Munemura","year":"1989","unstructured":"Munemura M, Agui T, Sibley DR (1989) Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. Endocrinology 124(1):346\u2013355. https:\/\/doi.org\/10.1210\/endo-124-1-346","journal-title":"Endocrinology"},{"issue":"3","key":"1165_CR19","doi-asserted-by":"publisher","first-page":"1097.e13","DOI":"10.1016\/j.fertnstert.2010.01.076","volume":"94","author":"K Garc\u00eda-Malpartida","year":"2010","unstructured":"Garc\u00eda-Malpartida K, Mart\u00edn-Gorgojo A, Rocha M, G\u00f3mez-Balaguer M, Hern\u00e1ndez-Mijares A (2010) Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertil Steril 94(3):1097.e13-1097.e15. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.01.076","journal-title":"Fertil Steril"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000318494","volume":"38","author":"P Fainstein Day","year":"2010","unstructured":"Fainstein Day P, Glerean M, Lovazzano S et al (2010) Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Front Horm Res 38:50\u201358. https:\/\/doi.org\/10.1159\/000318494","journal-title":"Front Horm Res"},{"issue":"6","key":"1165_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","volume":"172","author":"E Delgrange","year":"2015","unstructured":"Delgrange E, Vasiljevic A, Wierinckx A et al (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791\u2013801. https:\/\/doi.org\/10.1530\/EJE-14-0990","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1165_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/acta.0.1010491","volume":"101","author":"W Volker","year":"1982","unstructured":"Volker W, Gehring WG, Berning R, Schmidt RC, Schneider J, M\u00fchlenvon zur A (1982) Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol (Copenh) 101(4):491\u2013500","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"5","key":"1165_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000123324","volume":"34","author":"SWJ Lamberts","year":"1982","unstructured":"Lamberts SWJ, Verleun T, Oosterom R (1982) Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 34(5):339\u2013342. https:\/\/doi.org\/10.1159\/000123324","journal-title":"Neuroendocrinology"},{"issue":"7","key":"1165_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.4158\/EP-2018-0321","volume":"25","author":"C Choudhary","year":"2019","unstructured":"Choudhary C, Hamrahian AH, Bena JF, Recinos P, Kennedy L, Dobri G (2019) The effect of raloxifene on serum prolactin level in patients with prolactinoma. Endocr Pract 25(7):684\u2013688. https:\/\/doi.org\/10.4158\/EP-2018-0321","journal-title":"Endocr Pract"},{"issue":"11","key":"1165_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18112299","volume":"18","author":"MJ Garc\u00eda-Barrado","year":"2017","unstructured":"Garc\u00eda-Barrado MJ, Blanco EJ, Iglesias-Osma MC et al (2017) Relation among aromatase P450 and tumoral growth in human prolactinomas. Int J Mol Sci 18(11):1\u201316. https:\/\/doi.org\/10.3390\/ijms18112299","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1165_CR26","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2002-020426","volume":"87","author":"MP Gillam","year":"2002","unstructured":"Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87(10):4447\u20134451. https:\/\/doi.org\/10.1210\/jc.2002-020426","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1165_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4158\/EP10026.CR","volume":"16","author":"Z Heidari","year":"2010","unstructured":"Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract 16(4):669\u2013672. https:\/\/doi.org\/10.4158\/EP10026.CR","journal-title":"Endocr Pract"},{"key":"1165_CR28","unstructured":"Horos - DICOM software. https:\/\/horosproject.org\/download-horos\/."},{"key":"1165_CR29","unstructured":"DeLellis R. Pathology and Genetics of Tumours of Endocrine Organs. (WHO classification of tumors, ed.). IARC Press Lyon; 2004."},{"issue":"1","key":"1165_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17925\/EE.2019.15.1.30","volume":"15","author":"EV Varlamov","year":"2019","unstructured":"Varlamov EV, McCartney S, Fleseriu M (2019) Functioning pituitary adenomas - current treatment options and emerging medical therapies. Eur Endocrinol 15(1):30\u201340. https:\/\/doi.org\/10.17925\/EE.2019.15.1.30","journal-title":"Eur Endocrinol"},{"issue":"3","key":"1165_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2019","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al (2019) Surgery as a viable alternative first-line treatment for prolactinoma patients a systematic review and meta-analysis. J Clin Endocrinol Metab 105(3):1\u201310. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1165_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-3997000000032","volume":"62","author":"L Vilar","year":"2018","unstructured":"Vilar L, Abucham J, Albuquerque JL et al (2018) Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the neuroendocrinology department of the brazilian society of endocrinology and metabolism. Arch Endocrinol Metab. 62(2):236\u2013263. https:\/\/doi.org\/10.20945\/2359-3997000000032","journal-title":"Arch Endocrinol Metab."},{"issue":"4","key":"1165_CR33","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S et al (2014) Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290. https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1165_CR34","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/jc.85.6.2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247\u20132252. https:\/\/doi.org\/10.1210\/jc.85.6.2247","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1165_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22010021","volume":"22","author":"V Ide","year":"2021","unstructured":"Ide V, Vanderschueren D, Antonio L (2021) Treatment of men with central hypogonadism: Alternatives for testosterone replacement therapy. Int J Mol Sci 22(1):1\u201313. https:\/\/doi.org\/10.3390\/ijms22010021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1165_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40801-015-0028-3","volume":"2","author":"SA Hollingworth","year":"2015","unstructured":"Hollingworth SA, McGuire TM, Pache D, Eadie MJ (2015) Dopamine agonists: time pattern of adverse effects reporting in Australia. Drugs - Real World Outcomes 2(3):199\u2013203. https:\/\/doi.org\/10.1007\/s40801-015-0028-3","journal-title":"Drugs - Real World Outcomes"},{"key":"1165_CR37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01071","author":"CE Stiles","year":"2018","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM (2018) A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2018-01071","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1165_CR38","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104(7):2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1165_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00682745","volume":"30","author":"PV Plourde","year":"1994","unstructured":"Plourde PV, Dyroff M, Dukes M (1994) Arimidex\u00ae: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30(1):103\u2013111. https:\/\/doi.org\/10.1007\/BF00682745","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1165_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-020-00971-2","volume":"22","author":"Z Raptopoulos","year":"2020","unstructured":"Raptopoulos Z, Constantinou C (2020) The effect of exercise on the alleviation of side effects induced by aromatase inhibitors in postmenopausal breast cancer patients. Curr Oncol Rep 22(11):110. https:\/\/doi.org\/10.1007\/s11912-020-00971-2","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1165_CR41","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) THERAPY OF ENDOCRINE DISEASE: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175(3):R89\u2013R96. https:\/\/doi.org\/10.1530\/EJE-16-0087","journal-title":"Eur J Endocrinol"},{"key":"1165_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01478-0","author":"G Beccuti","year":"2020","unstructured":"Beccuti G, Guaraldi F, Natta G et al (2020) Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-020-01478-0","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1165_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M et al (2017) Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary 20(5):489\u2013498. https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"},{"key":"1165_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/165215","volume":"2015","author":"V Rochira","year":"2015","unstructured":"Rochira V, Kara E, Carani C (2015) The endocrine role of estrogens on human male skeleton. Int J Endocrinol 2015:165215. https:\/\/doi.org\/10.1155\/2015\/165215","journal-title":"Int J Endocrinol"},{"issue":"12","key":"1165_CR45","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1210\/jc.2009-0739","volume":"94","author":"SAM Burnett-Bowie","year":"2009","unstructured":"Burnett-Bowie SAM, McKay EA, Lee H, Leder BZ (2009) Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 94(12):4785\u20134792. https:\/\/doi.org\/10.1210\/jc.2009-0739","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1165_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","volume":"46","author":"M Marazuela","year":"2014","unstructured":"Marazuela M, Ramos-Lev\u00ed A, Sampedro-N\u00fa\u00f1ez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46(2):215\u2013219. https:\/\/doi.org\/10.1007\/s12020-014-0206-1","journal-title":"Endocrine"},{"issue":"2","key":"1165_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","volume":"46","author":"L Kasuki","year":"2014","unstructured":"Kasuki L, Vieira Neto L, Gadelha MR (2014) Cabergoline treatment in acromegaly: cons. Endocrine 46(2):220\u2013225. https:\/\/doi.org\/10.1007\/s12020-014-0183-4","journal-title":"Endocrine"},{"issue":"8","key":"1165_CR48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1517\/14656566.2013.784744","volume":"14","author":"RS Jallad","year":"2013","unstructured":"Jallad RS, Bronstein MD (2013) The place of medical treatment of acromegaly: current status and perspectives. Expert Opin Pharmacother 14(8):1001\u20131015. https:\/\/doi.org\/10.1517\/14656566.2013.784744","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1165_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4158\/EP-2017-0195","volume":"24","author":"M Imani","year":"2018","unstructured":"Imani M, Khamseh ME, Asadi P et al (2018) Comparison of cabergoline versus raloxifene add-on therapy to long-acting somatostatin analogue in patients with inadequately controlled acromegaly: a randomized open label clinical trial. Endocr Pract 24(6):542\u2013547. https:\/\/doi.org\/10.4158\/EP-2017-0195","journal-title":"Endocr Pract"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01165-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01165-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01165-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T05:20:54Z","timestamp":1635225654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01165-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01165-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740380508.793590508","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"17 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}